Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBITDA (2017 - 2025)

Lexaria Bioscience's EBITDA history spans 9 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 40.86% year-over-year to -$1.6 million; the TTM value through Nov 2025 reached -$10.8 million, down 47.63%, while the annual FY2025 figure was -$12.0 million, 105.54% down from the prior year.
  • EBITDA for Q4 2025 was -$1.6 million at Lexaria Bioscience, up from -$2.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$674537.0 in Q1 2024 and bottomed at -$3.8 million in Q2 2025.
  • The 5-year median for EBITDA is -$1.8 million (2022), against an average of -$1.9 million.
  • The largest annual shift saw EBITDA tumbled 1626.59% in 2021 before it surged 48.04% in 2024.
  • A 5-year view of EBITDA shows it stood at -$2.0 million in 2021, then increased by 12.36% to -$1.8 million in 2022, then skyrocketed by 33.09% to -$1.2 million in 2023, then plummeted by 130.38% to -$2.7 million in 2024, then surged by 40.86% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's EBITDA are -$1.6 million (Q4 2025), -$2.7 million (Q3 2025), and -$3.8 million (Q2 2025).